HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France Wants To Move Paracetamol, Ibuprofen And Aspirin Behind The Counter

Executive Summary

France's medicines agency wants to restrict sales of OTC drugs containing paracetamol, ibuprofen and aspirin to behind the pharmacy counter due to safety concerns.

You may also be interested in...



Dutch Parliament To Decide Future Of OTC Market

In January, the Dutch Parliament will debate an amendment to the country's medicines legislation that proposes to remove the requirement for a druggist or assistant druggist to be physically present during the sale of self-care medicines. The move will once again allow supermarkets to sell UAD medicines, with the help of digital tablets offering professional advice, hastening the transformation of the Dutch OTC market, according to Neprofarm's Bernard Mauritz.

Government Skepticism And Over Regulation Holding Back Self-Care In France – GSCF Analysis

France's self-medication market lags behind its European rivals. Why is that? A skeptical and over-cautious government and a stifling regulatory system may provide at least part of the answer, the Global Self-Care Federation's recently published Self-Care Readiness Index suggests.  

France Moving Paracetamol and NSAIDs Behind Pharmacy Counter From January

Fears over patient safety will see common OTC drugs including paracetamol moved behind the counter in France from January 2020.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel